Previous 10 | Next 10 |
ClearPoint Neuro, Inc. (CLPT) Q4 2022 Earnings Conference Call March 01, 2023 04:30 PM ET Company Participants Joe Burnett - CEO Danilo D’Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Neil Chatterji - B. R...
ClearPoint Neuro press release ( NASDAQ: CLPT ): FY GAAP EPS of -$0.68 beats by $0.02 . Revenue of $20.55M (+26.1% Y/Y) misses by $0.03M . For further details see: ClearPoint Neuro GAAP EPS of -$0.68 beats by $0.02, revenue of $20.55M misses by $0.03M
SOLANA BEACH, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced financial results for its fourth quarter and full-year ended Dec...
ClearPoint Neuro ( NASDAQ: CLPT ) is scheduled to announce Q4 earnings results on Wednesday, March 1st, after market close. The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $5.19M Over the last 3 months, EPS estimates have seen 0 upward revisions ...
SOLANA BEACH, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2022 fourth quarte...
Summary ClearPoint Neuro is a growth story and should be evaluated as such. I break down some of the growth factors that I consider most important. I also review the company valuation and cash position in explaining how I come to my "Buy" rating. For further de...
ClearPoint Neuro ( NASDAQ: CLPT ) expects Q4 revenue to increase 21% year-over-year to $5.2M compared to consensus estimate of $5.8M . Biologics and drug delivery revenue is estimated to grow 37% Y/Y to $2.3M, while functional neurosurgery products and services revenue increas...
SOLANA BEACH, Calif., Jan. 11, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced preliminary, unaudited financial results for its fourth quarter a...
ClearPoint Neuro ( NASDAQ: CLPT ) on Monday announced the enrollment of the first patient in a Glioblastoma clinical trial using the ClearPoint Prism Neuro Laser Therapy System. The Laser Thermal Ablation of Brain Lesions study is a single-arm trial evaluating the safety and feasi...
SOLANA BEACH, Calif., Dec. 12, 2022 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced enrollment of the first patient in a Glioblastoma clinical trial ...
News, Short Squeeze, Breakout and More Instantly...
ClearPoint Neuro, Inc. Company Name:
CLPT Stock Symbol:
NASDAQ Market:
ClearPoint Neuro, Inc. Website:
SOLANA BEACH, Calif., July 17, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced that it will release financial results for its ...
2024-07-15 17:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...